Background: Programmed cell death protein-1-targeted immunotherapy has shown
| INTRODUC TI ON
Hepatocellular carcinoma (HCC) represents the most common primary liver cancer and usually develops in patients suffering from underlying chronic liver disease. [1] [2] [3] [4] [5] Despite recommendations for surveillance of patients at risk, HCC is often diagnosed at an advanced stage where only systemic treatment can be offered. Many patients develop recurrence or disease progression after initial surgical or loco-regional treatment and then become candidates for palliative systemic therapy. 1, 5, 6 For the last decade, the tyrosine kinase inhibitor sorafenib was the only effective drug available for HCC, 6 with two randomised controlled phase III trials showing a survival benefit compared to placebo. 7, 8 Only recently, three more tyrosine kinase inhibitors were approved for HCC, lenvatinib in first-line and regorafenib and cabozantinib in second-line drug treatment. [9] [10] [11] Ramucirumab, a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR)-2, improved survival in a secondline phase III study of patients with advanced HCC and elevated alpha-fetoprotein, 12 and thus will likely be included in the treatment algorithm shortly.
Immunotherapy with checkpoint blockers demonstrated encouraging efficacy in certain cancer types, particularly in melanoma and lung cancer. 13 HCC may also be an attractive candidate for immunotherapy, as it represents an immunogenic tumour, but also fosters an immunosuppressive microenvironment (eg, by up-regulation of immune checkpoint molecules). This may be further supported by the tolerogenic liver milieu and chronic inflammation due to the underlying liver disease. 6, [14] [15] [16] Notably, overexpression of the checkpoint molecules programmed cell death-ligand 1 (PD-L1) and programmed cell death protein-1 (PD-1) was associated with tumour aggressiveness and postoperative recurrence in HCC. 17, 18 Nivolumab and pembrolizumab, two monoclonal antibodies against PD-1, have shown promising efficacy and safety results in noncomparative, open-label phase II studies of advanced HCC, 19, 20 and the United States Food and Drug Administration (FDA) already granted accelerated conditional approval to both agents for sorafenib-experienced patients with HCC. Both nivolumab and pembrolizumab are currently being investigated in ongoing phase III trials.
In the present study, we aimed to analyse the safety and efficacy of anti-PD-1 targeted therapy with nivolumab or pembrolizumab in an international, multicentre, real-life cohort of patients with advanced HCC. In contrast to the phase II studies of nivolumab and pembrolizumab, 19, 20 our cohort also includes patients with more advanced liver cirrhosis (Child-Pugh B/C) as well as patients who received immunotherapy as third or even fourth line of systemic therapy. Thus, this cohort reflects the treatment reality in advanced HCC outside of clinical trial programs.
| PATIENTS AND ME THODS

| Study design and patients
This was a retrospective study of patients treated with nivolumab or pembrolizumab across six centres in Austria and Germany. Patients with histologically or radiologically confirmed HCC 1 who received PD-1-targeted immunotherapy with nivolumab or pembrolizumab were eligible. All data, including patient history, laboratory results and radiological information were collected retrospectively. The retrospective analysis was approved by local Ethics Committees.
| Dosing of nivolumab and pembrolizumab
Nivolumab was administered at 1-3 mg/kg body weight or at a fixed dose of 240 mg every 2 weeks intravenously. Pembrolizumab was given at 2 mg/kg body weight or at a fixed dose of 200 mg every 3 weeks intravenously. Dose delays were made based on toxicity.
| Assessments
Radiological response was recorded by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, 6-12 weeks after treatment initiation, and about every 3 months thereafter.
Tumour response was assessed according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST). 21 Patients with progressive disease of target lesions (increase of at least 20%) at the first radiological evaluation were assessed for hyperprogressive disease.
Hyperprogression was defined as a progressive disease (RECIST version 1.1 22 ) on the first radiological evaluation during immunotherapy with a delta tumour growth rate of > 50%, corresponding to an absolute increase in tumour growth rate exceeding 50% per month.
23 diarrhoea (n = 3) and hepatitis (n = 3 
| Statistics
| RE SULTS
| Patients
Sixty-five patients in whom PD-1 targeted immunotherapy was initiated between July 10, 2015 and April 27, 2018 were included.
The date of data cut-off was December 31, 2018. Thirty-four subjects received nivolumab and 31 patients were treated with pembrolizumab ( Figure 1 ). Main baseline characteristics are shown in Table 1 . Immunotherapy was used as systemic first-, second-, third-, or fourth-line treatment in 9 (14%), 27 (42%), 26 (40%) and 3 (5%) patients respectively. Agents used for prior systemic therapy are shown in Table S1 . Fifty-one (79%) patients had advanced stage HCC and a significant number of patients had Child-Pugh stage B/C (n = 33; 51%).
Median duration of follow-up was 11.2 (95% CI, 9.9-12.6) months.
Median time of treatment was 3.1 (95% CI, 2.5-3.6) months for nivolumab and 2.8 (95% CI, 0-5.7) months for pembrolizumab. At data cut-off, 2 (6%) and 9 (29%) patients were still on treatment with nivolumab and pembrolizumab respectively. Immunotherapy was discontinued mainly due to radiological or clinical disease progression (nivolumab and pembrolizumab, n = 23 (68%) and n = 14 (45%)) and adverse events (nivolumab and pembrolizumab, n = 6 (18%) and n = 1 (3%)). After discontinuation of immunotherapy, 21 (32%) patients received an alternative treatment. The following therapies were used: regorafenib (n = 5), lenvatinib (n = 5), ramucirumab (n = 4), radiation (n = 4), sorafenib (n = 2), cabozantinib (n = 2), capecitabine (n = 2), gemcitabine plus cisplatin (n = 1), microwave ablation (n = 1) and SIRT (n = 1).
| Efficacy
Fifty-four patients had at least one follow-up imaging and were therefore available for radiological tumour response assessment (nivolumab, n = 30; pembrolizumab, n = 24). Of the 11 subjects not available for response assessment, 9 patients died before the first radiological evaluation and 2 patients were lost to follow-up. In the nivolumab group, no patient had complete response (CR) and 5 (15%) participants achieved partial response (PR), resulting in an overall response rate (ORR) of 15%. Ten (29%) patients showed stable disease (SD) and 15 (44%) subjects had progressive disease at first radiological evaluation. The disease control rate (DCR) was 44%. In the pembrolizumab-treated patients, 0 and 3 (10%) participants achieved complete response and partial response, respectively. Fourteen (45%) patients had stable disease and 7 (23%) individuals showed progressive disease. The overall response rate and disease control rate were 10% and 55% respectively.
The overall response rate and disease control rate for the whole cohort were 12% and 49% respectively ( Table 2) . Of 54 patients with at least one follow-up imaging, 52 patients were evaluable for hyperprogression (nivolumab, n = 28; pembrolizumab, n = 24), of which 4 (8%) subjects were classified as having hyperprogressive disease (nivolumab, n = 2 (7%); pembrolizumab, n = 2 (8%)).
Overall, 35 (54%) patients had radiological disease progression and 36 (55%) participants died during follow-up. Median time to progression was 5.5 (95% CI, 3.5-7.4) months for the whole cohort (Figure 2 ), 4.6 (95% CI, 1.9-7.4) months for nivolumab and 6.4
(95% CI, 3.4-9.5) months for pembrolizumab ( Figure 3 , Table 2 ).
Progression-free survival was 4.6 (95% CI, 3.0-6.2) months for the whole group (Figure 4) , and 4.3 (95% CI, 2.0-6.7) months and 5.6
(95% CI, 1.1-10.1) months for nivolumab and pembrolizumab respectively ( Figure 5 , Table 2 ). Median overall survival was 11.0 (95% CI, 8.2-13.8) months for the whole cohort (Figure 6 ), 9.0 (95% CI, 5.5-12.5) months for nivolumab, and 11.0 (95% CI, 7.4-14.5) months for pembrolizumab ( Figure 7 , Table 2 ).
Median OS for patients with partial response or stable disease was 16.2 (95% CI, 9.1-23.3) months and was significantly longer compared to that of patients with progressive disease, which was 7.4
(95% CI, 6.3-8.5; P = 0.039) months (Figure 8 ).
| Safety
Twenty-five (39%) patients experienced at least one adverse event (AE). Most common adverse events were infections (n = 7; 11%), rash (n = 6; 9%), pruritus (n = 3; 5%), fatigue (n = 3; 5%), diarrhoea (n = 3; 5%) and hepatitis (n = 3; 5%). All cases of hepatitis were treated with corticosteroids. Eleven (17%) patients developed adverse events of higher grade (grade ≥ 3). Adverse events observed in nivolumab-and pembrolizumab-treated patients are shown in Table 3 . One patient died due to an infection; a relationship to pembrolizumab is unlikely but cannot be excluded. A dose delay due to adverse events was required in 6 (18%) patients treated with nivolumab and in 11 (36%) participants receiving pembrolizumab. Steroids or immunosuppressive drugs were used to treat an adverse event in 5 (15%) nivolumaband 5 (16%) pembrolizumab-treated subjects.
| Efficacy and safety according to ChildPugh stage
As the number of patients with Child-Pugh stage C was too low (Table S2 ).
In terms of safety, there was no difference regarding the num- Table S3 .
| Efficacy and safety according to systemic line of immunotherapy
As the number of patients who received immunotherapy as first (n = 9) or fourth (n = 3) line of systemic treatment was low, we grouped patients who received immunotherapy as first-or secondline (group 1) and those in whom immunotherapy was used as thirdor fourth-line of systemic treatment (group 2).
Overall response rate and disease control rate for group 1 vs 2 was 11% vs 14% (P = 1.000) and 50% vs 48% (P = 0.901) respectively. (Table S4 ).
In terms of safety, the number of patients who developed any grade (Group 1 vs 2, n = 12 (33%) vs n = 13 (45%); P = 0.344) or highgrade (Group 1 vs 2, n = 6 (17%) vs n = 5 (17%); P = 1.000) adverse events was similar between group 1 and 2.
| D ISCUSS I ON
We demonstrate that PD-1-targeted immunotherapy with nivolumab or pembrolizumab showed promising efficacy and mild toxicity in a 100% and about 90% respectively. 19, 24, 25 Based on these promising data, nivolumab was conditionally approved for HCC previ- Monoclonal antibodies are not metabolized by the liver but eliminated predominantly via uptake and catabolism by the reticuloendothelial system and target tissue. 26 This could make the pharmacokinetic profile of immune checkpoint inhibitors more predictable even in patients with advanced liver cirrhosis. 15 However, inter alia by an upregulation of immune checkpoint molecules. 31, 32 Indeed, sorafenib intensified tumour hypoxia and increased tumoural PD-L1 expression in experimental models of HCC. 33, 34 Thus, immunotherapy may be particularly attractive following or combined with anti-vascular endothelial growth factor (VEGF)-targeted therapies.
In line, preliminary data of pilot studies testing the combination of lenvatinib plus pembrolizumab (n = 26) and bevacizumab combined with atezolizumab (n = 68) showed encouraging response rates of 42% and 34% respectively. 35, 36 Hyperprogressive disease-an increased tumour growth rate during treatment-is a new pattern of progression that was recently reported for patients treated with PD-1-/PD-L1-targeted immunotherapy. 23, 37, 38 Four (8%) patients in our cohort had hyperprogression during immunotherapy. This is in line with a previous study that reported hyperprogressive disease in 9% of patients with advanced cancers, 37 but lower compared to recurrent and/or metastatic head and neck cancer (29%) 38 and advanced non-small-cell lung cancer (13.8%) treated with PD-1/PD-L1 blockers. 23 Notably, hyperprogressive disease was defined differently in these studies as there is currently no consensus on the optimal definition. 23, 37, 38 The underlying mechanisms for hyperprogressive disease are unknown, but it was hypothesised that major immune reactions, promotion of tumour cell proliferation, immune compensatory mechanisms and prior irradiation may play a role in hyperprogression with PD-1-/PD-L1-targeted therapy. 37, 38 Despite the retrospective nature and the lack of a control group, the strength of our study is the provision of unique real-world data 
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